Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
mehreen.datoo@ndm.ox.ac.uk

Research groups

Malaria Programme: Pre-erythrocytic Vaccines

Mehreen Datoo

Clinical Research Fellow and DPhil Student

Recent publications

Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial

Kapulu MC. et al, (2026), Nature Medicine, 32, 178 - 185

Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials

Venkatraman N. et al, (2025), The Lancet Microbe, 6, 100868 - 100868

Acceptability of the R21/Matrix-M malaria vaccine alongside existing malaria interventions in the trial context.

Diawara H. et al, (2025), BMJ global health, 10

The R21/Matrix-M malaria vaccine: questions remain - Author's reply.

Datoo MS. et al, (2025), Lancet (London, England), 405, 299 - 301

Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults

Silman D. et al, (2024), Wellcome Open Research, 9, 734 - 734